Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Dihomo-gamma-linolenic acid (DGLA) is an omega-6 fatty acid that serves as an intermediate in the metabolism of linoleic acid and gamma-linolenic acid (GLA). Some scientific interest exists regarding its potential anti-inflammatory effects, particularly in conditions like rheumatoid arthritis (RA). DGLA can be converted to anti-inflammatory eicosanoids, such as prostaglandin E1 (PGE1), which is thought to modulate immune response and decrease inflammation.

However, direct clinical evidence supporting the use of DGLA supplementation specifically for RA is limited. Most human studies have focused on GLA-containing oils (such as evening primrose oil or borage oil), which are metabolized to DGLA in the body. Some of these studies have shown modest improvements in symptoms of RA, but results are inconsistent and sample sizes are often small. Furthermore, the benefit is generally attributed to the downstream anti-inflammatory effects of DGLA, rather than robust direct evidence for DGLA itself.

Major clinical guidelines do not currently endorse DGLA (or GLA) as a standard therapy for RA, and systematic reviews conclude that while there may be some anti-inflammatory potential, the evidence is not strong enough to firmly recommend its use. Thus, while there is a scientific rationale and some limited supporting data, the evidence base remains modest (rated 2/5).

More about Dihomo-gamma-linolenic acid
More about Rheumatoid Arthritis

Other ingredients used for Rheumatoid Arthritis

Other health conditions supported by Dihomo-gamma-linolenic acid

Products containing Dihomo-gamma-linolenic acid